NanoXplore's U.S. Subsidiary Enters Into a Consent Order With U.S. EPA

NanoXplore Inc. (" NanoXplore " or the " Corporation ") (TSX: GRA and OTCQX: NNXPF) announces that on August 13, 2021, its U.S. subsidiary RMC Advanced Technologies Inc. entered into a consent order with the U.S. Environmental Protection Agency (" EPA ") under the Toxic Substances Control Act (TSCA) (the " Consent Order "), which Consent Order allows for the commercial use of its GrapheneBlack TM as an additive for thermoplastics, thermosets and rubbers, with no annual volume limitation.

Soroush Nazarpour, President and Chief Executive Officer of NanoXplore, commented:

"This long-awaited news constitutes a significant milestone for NanoXplore, as it opens the GrapheneBlack TM market in the U.S. It marks a historic year for us: Eleven years after graphene winning the Nobel Prize, NanoXplore's graphene reaches regulatory approval for industrial volumes in the U.S."

About NanoXplore Inc.

NanoXplore is a graphene company, a manufacturer and supplier of high-volume graphene powder for use in industrial markets. The Corporation provides standard and custom graphene-enhanced plastic and composite products to various customers in transportation, packaging, electronics, and other industrial sectors. NanoXplore is headquartered in Montreal, Quebec with manufacturing facilities in Canada, the United States and Europe.

For more information, please contact:

Soroush Nazarpour
President and Chief Executive Officer
NanoXplore Inc.
(514) 935-1377
info@NanoXplore.ca


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Determined maximum tolerated dose (MTD) in Phase 1 monotherapy study of NUV-868; Phase 1b studies of NUV-868 in combination with olaparib or enzalutamide remain ongoing

Received U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug (IND) application for NUV-1511, the first clinical candidate from our novel drug-drug conjugate (DDC) platform

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors

Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Robert Mashal, M.D. to its Board of Directors.

"We are delighted to have Dr. Mashal join our Board of Directors," said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio. "Robert is a seasoned biotech industry veteran and his experience as an investor, operator, and medical oncologist will provide us with valuable insights. We look forward to working with Robert to advance Nuvation's pipeline."

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors

Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors

NUV-1511 is the first clinical candidate from the company's novel drug-drug conjugate platform

Company anticipates initiating a Phase 1/2 clinical study of NUV-1511 in 1H 2024

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

NanoXplore Receives TSX Approval for Normal Course Issuer Bid

NanoXplore Inc. (TSX: GRA) ("NanoXplore" or the "Corporation") is pleased to announce that the Toronto Stock Exchange (TSX) has approved the Corporation's request to adopt a normal course issuer bid (NCIB) program, through which NanoXplore may purchase, for cancellation, up to 5,936,205 common shares or approximately 5% of the public float (consisting of 118,724,119 common shares as of November 22, 2023, out of the 169,378,431 common shares issued and outstanding). The Corporation may purchase shares under the NCIB over a period of twelve months commencing on December 1, 2023 and ending November 30, 2024, when the bid expires. NCIB purchases are through the facilities of the TSX and certain Canadian Alternative Trading Systems and the price for any repurchased shares will be the prevailing market price at the time of the acquisition.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

NanoXplore Unveils a Large-Scale Dry Process for Manufacturing of Graphene: An Improvement for Cost Competitiveness and Scalability

NanoXplore Inc. ("NanoXplore" or "the Corporation") (TSX: GRA and OTCQX: NNXPF), a world-leading graphene company, proudly announces an interesting achievement in graphite exfoliation with the successful development of a novel dry graphene manufacturing process.

The dry process centers on an advanced exfoliation technology with innovative media that enables high yield exfoliation without the introduction of impurities.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

NanoXplore Reports Results for its Q1-2024

NanoXplore Inc. ("NanoXplore" or "the Corporation") (TSX: GRA and OTCQX: NNXPF), a world-leading graphene company, reported today financial results for the three-month period ended September 30, 2023.

All amounts in this press release are in Canadian dollars, unless otherwise stated.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×